| Drug Name | 
								Cinacalcet hydrochloride | 
							
							
								| Drug ID | 
								BADD_D00469 | 
							
							
								| Description | 
								Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure. | 
							
							
								| Indications and Usage | 
								For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma. | 
							
							
								| Marketing Status | 
								approved | 
							
				
							
								| ATC Code | 
								H05BX01 | 
							
							
								| DrugBank ID | 
								
									DB01012
								 | 
							
							
								| KEGG ID | 
								
									D03505
								 | 
							
							
								| MeSH ID | 
								
								
									D000069449
								 	
								
								 | 
							
							
								| PubChem ID | 
								
									156418
								 | 
							
							
								| TTD Drug ID | 
								
									D03YGR
								 | 
							
							
								| NDC Product Code | 
								65372-1165; 65977-0110; 50090-3529; 58159-055; 65862-799; 68259-1302; 55513-073; 71093-154; 63126-910; 55513-075; 53747-056; 65085-0052; 49706-2030; 65096-0114; 16436-0082; 55513-074; 70436-007; 71093-152; 53104-7699; 53296-0082; 71093-153; 50379-0016; 55111-959; 63415-0528; 70436-008; 70436-009 | 
							
							
								| UNII | 
								
                                    1K860WSG25
                                 | 
							
							
								| Synonyms | 
								Cinacalcet | Cinacalcet Hydrochloride | Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride | Sensipar | AMG 073 | KRN 1493 | AMG073 |